Trial Profile
A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Rezvilutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 12 May 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 12 May 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 12 May 2020 Status changed from recruiting to active, no longer recruiting.